Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05744466 · ClinicalTrials.gov registry record
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
A clinical trial of Psoriasis, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- 1,500
- Enrollment target
- 1
- Study location
NCT05744466 is a study of Psoriasis that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 1,500 participants, above the 477-participant average among 125 other Psoriasis trials with a reported enrollment target (214% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05744466, a study of Psoriasis, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand the comparative effectiveness of deucravacitinib versus apremilast in adults with plaque psoriasis.
Conditions Studied
Interventions
- DRUG Deucravacitinib
- DRUG Apremilast
Study Locations (1)
Massachusetts
- Local Institution - Waltham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2022-09-30 |
| Est. Completion | 2027-12-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05744466
The ClinicalTrials.gov registry entry for NCT05744466 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 477-participant average among 125 other Psoriasis trials with a reported enrollment target (214% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Deucravacitinib is the first listed.
NCT05744466 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05744466 about?
NCT05744466 is a clinical study titled "A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis". The purpose of this study is to understand the comparative effectiveness of deucravacitinib versus apremilast in adults with plaque psoriasis.
What is the current status of trial NCT05744466?
This trial is currently recruiting. The enrollment target is 1,500 participants. The study started on 2022-09-30. Estimated completion is 2027-12-10.
What conditions does trial NCT05744466 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT05744466?
The interventions under investigation include: Deucravacitinib (DRUG), Apremilast (DRUG).
Who is sponsoring clinical trial NCT05744466?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05744466 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Use of Total-Body PET to Quantify Systemic and Cutaneous Inflammation in Psoriasis Patients Before and After Intervention With a Nutritionally Balanced Diet
RECRUITING · NA
-
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
RECRUITING
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.